Tracer kinetic analysis of (S)-18F-THK5117 as a PET tracer for assessing tau pathology

Journal of Nuclear Medicine

Volumn 57, Issue 4, 2016, Pages 574-581

  Jonasson, My ^a,b   Wall, Anders ^a,b   Chiotis, Konstantinos ^c   Saint Aubert, Laure ^c   Wilking, Helena ^b   Sprycha, Margareta ^b   Borg, Beatrice ^b   Thibblin, Alf ^b   Eriksson, Jonas ^a,b   Sörensen, Jens ^a,b   Antoni, Gunnar ^a,b   Nordberg, Agneta ^c,d   Lubberink, Mark ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Kinetic modeling; Parametric images; Positron emission tomography; Tau

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 11; FLUORINE THK 5117 F 18; TAU PROTEIN; TRACER; UNCLASSIFIED DRUG; 6-((3-FLUORO-2-HYDROXY)PROPOXY)-2-(4-METHYLAMINOPHENYL)QUINOLINE; ANILINE DERIVATIVE; QUINOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BINDING KINETICS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; FEASIBILITY STUDY; FEMALE; GRAY MATTER; HUMAN; MALE; MEASUREMENT PRECISION; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOKINETIC PARAMETERS; PLASMA TO WHOLE BLOOD RATIO; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RADIOSYNTHESIS; SIMULATION; TAUOPATHY; TISSUE TIME ACTIVITY CURVE; TISSUE TO CEREBELLUM RATIO OVER TIME; TISSUE TO UNMETABOLIZED TRACER IN PLASMA RATIO; VOXEL BASED MORPHOMETRY; WHITE MATTER; WHOLE BLOOD TIME ACTIVITY CURVE; BRAIN CORTEX; CEREBELLUM; COMPUTER ASSISTED DIAGNOSIS; COMPUTER SIMULATION; METABOLISM; PUTAMEN; REPRODUCIBILITY; SCINTISCANNING; SYNTHESIS;

AGED; ALZHEIMER DISEASE; ANILINE COMPOUNDS; CEREBELLUM; CEREBRAL CORTEX; COMPUTER SIMULATION; FEMALE; GRAY MATTER; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; QUINOLINES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TAU PROTEINS; TAUOPATHIES;

EID: 84963945616     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.158519     Document Type: Article

References (25)

1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.
2. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630-1645.
3. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
4. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13: 614-629.
5. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631-639.
6. Jack CR, Wiste HJ, Lesnick TG, et al. Brain b-amyloid load approaches a plateau. Neurology. 2013;80:890-896.
7. Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging in Alzheimer's disease. Curr Neurol Neurosci Rep. 2014;14:500.
8. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114-124.
9. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094-1108.
10. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34: 457-468.
11. 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420-1427.
12. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56:303-308.
13. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194.
14. Nordberg A, Carter SF, Rinne J, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2013;40: 104-114.
15. Svarer C, Madsen K, Hasselbalch SG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage. 2005;24:969-979.
16. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716-723.
17. Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6:461-464.
18. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10: 740-747.
19. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
20. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
21. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279-287.
22. Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab. 2002;22: 1440-1452.
23. 18F]T807 [abstract]. J Nucl Med. 2015;56(suppl 3):414.
24. 11Clabeled Pittsburgh compound B. J Nucl Med. 2011;52:393-400.
25. Forsberg A, Engler H, Blomquist G, Langström B, Nordberg A. The use of PIBPET as a dual pathological and functional biomarker in AD. Biochim Biophys Acta. 2012;1822:380-385.